Literature DB >> 6344747

Viability, heat stability and immunogenicity of four BCG vaccines prepared from four different BCG strains.

M Gheorghiu, P H Lagrange.   

Abstract

Four BCG strains, French 1173-P2, Danish 1331, Japanese 172 and Glaxo-1077, among those most widely used throughout the world for tuberculosis vaccination, were prepared according to the respective conditions in each BCG-production unit. These 16 vaccine preparations were distributed and compared using standardized in vitro and in vivo conditions, based on optical density and bacillary mass/ml. The results presented in this report concern only the 4 freeze-dried BCG strains prepared by the Institut Pasteur BCG unit. It is shown that these 4 preparations differ in their in vitro characteristics such as growth, morphology, heat stability and viability, tested by colony-forming units and the ATP content. In addition, statistically significant differences were observed in biological control tests performed in guinea-pigs and mice when they were immunized with the same concentrations of 4 reconstituted vaccines. For instance, in tests measuring hallmarks of cell-mediated immunity--such as local granuloma formation, spleen index, delayed-type hypersensitivity to tuberculin, and non-specific immunopotentiation to unrelated antigen--a ranking order of relative immunopotency of the four strains was made, giving the following classification in decreasing order: French 1173-P2, Danish 1331, Japanese 172 and Glaxo-1077. Specific acquired resistance after BCG vaccination in mice was obtained with all four vaccines. However, higher protection was observed in mice vaccinated with Glaxo-1077 and French 1173-P2 strains. No obvious correlation existed between the intensity of cellular post-vaccination resistance and the above CMI tests, except those concerning the three-week index of BCG infection measured in the spleen, which correlated with the protection test.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6344747     DOI: 10.1016/s0769-2625(83)80157-3

Source DB:  PubMed          Journal:  Ann Immunol (Paris)        ISSN: 0300-4910


  13 in total

1.  Strain-dependent variation in Mycobacterium bovis BCG-induced human T-cell activation and gamma interferon production in vitro.

Authors:  Ana M Aguirre-Blanco; Pauline T Lukey; Jacqueline M Cliff; Hazel M Dockrell
Journal:  Infect Immun       Date:  2007-03-26       Impact factor: 3.441

2.  New developments in BCG vaccine: implications for tuberculosis control.

Authors:  C R MacIntyre
Journal:  Epidemiol Infect       Date:  2007-02       Impact factor: 2.451

3.  Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety.

Authors:  J B Milstien; J J Gibson
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

4.  Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains.

Authors:  M R Lagranderie; A M Balazuc; E Deriaud; C D Leclerc; M Gheorghiu
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

5.  Resistance of high and low antibody responder lines of mice to the growth of avirulent (BCG) and virulent (H37Rv) strains of mycobacteria.

Authors:  M Gheorghiu; D Mouton; H Lecoeur; M Lagranderie; J C Mevel; G Biozzi
Journal:  Clin Exp Immunol       Date:  1985-01       Impact factor: 4.330

6.  Synthesis, degradation, and antimicrobial properties of targeted macromolecular prodrugs of norfloxacin.

Authors:  Eveline Roseeuw; Veerle Coessens; Anne-Marie Balazuc; Micheline Lagranderie; Pierre Chavarot; Augusto Pessina; Maria Grazia Neri; Etienne Schacht; Gilles Marchal; Dominique Domurado
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

7.  Experimental screening of BCG preparations produced for cancer immunotherapy: safety and immunostimulating and antitumor activity of four consecutively produced batches.

Authors:  W H de Jong; P A Steerenberg; J G Kreeftenberg; R H Tiesjema; W Kruizinga; L M van Noorle Jansen; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

8.  Impact of in vitro evolution on antigenic diversity of Mycobacterium bovis bacillus Calmette-Guerin (BCG).

Authors:  Richard Copin; Mireia Coscollá; Sebastien Gagneux; Joel D Ernst; Efstratios Efstathiadis
Journal:  Vaccine       Date:  2014-09-06       Impact factor: 3.641

9.  Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis.

Authors:  T Mark Doherty; Anja Weinrich Olsen; Laurens van Pinxteren; Peter Andersen
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

10.  The Current Status of BCG Vaccination in Young Children in South Korea.

Authors:  Hyejon Lee; Hazel M Dockrell; Deok Ryun Kim; Sian Floyd; Sue Yeon Oh; Jin Bum Lee; Hee Jin Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2012-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.